China Pharma Holdings (CPHI) Capital Expenditures (2010 - 2025)

China Pharma Holdings (CPHI) has reported Capital Expenditures for 16 consecutive years, with $454.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 97.68% year-over-year to $454.0; the trailing twelve-month figure through Dec 2025 stood at $59324.0 (down 27.92% YoY), and the FY2025 full-year result was $59324.0, up 54.45% from the prior year.
• Capital Expenditures retreated to $454.0 in Q4 2025 per CPHI's latest filing, from $611.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $415977.0 in Q3 2021 and bottomed at -$55964.0 in Q1 2023.
• Historically, Capital Expenditures has averaged $56635.2 across 5 years, with a median of $2959.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures sank 4123.29% in 2023, then jumped 331.74% in 2024.
• Over 5 years, Capital Expenditures stood at $7056.0 in 2021, then sank by 486.45% to -$27268.0 in 2022, then surged by 116.6% to $4527.0 in 2023, then soared by 331.74% to $19545.0 in 2024, then plunged by 97.68% to $454.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $454.0, $611.0, and -$65.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.